Emerging and New Treatment Options for Knee Osteoarthritis

Osteoarthritis (OA) is the most prevalent type of arthritis worldwide, resulting in pain
and often chronic disability and a significant burden on healthcare systems globally. Non-steroidal
anti-inflammatory drugs (NSAIDs), analgesics, intra-articular corticosteroid injections are of little
value in the long term, and opioids may have ominous consequences. Radiotherapy of knee OA
has no added value. Physical therapy, exercises, weight loss, and lifestyle modifications may give
pain relief, improve physical functioning and quality of life. However, none of them has articular
cartilage regenerating potential. Due to a better understanding of osteoarthritis, innovative new
treatment options have been developed. In this narrative review, we focus on emerging OA knee
treatments, relieving symptoms, and regenerating damaged articular cartilage that includes intra-articular
human serum albumin, conventional disease-modifying anti-rheumatic drugs (DMARDs),
metformin, lipid-lowering agents (statin), nerve growth factors antagonists, bone morphogenetic
protein, fibroblast growth factors, Platelet-Rich Plasma (PRP), Mesenchymal Stem Cells (MSC),
exosomes, interleukin-1 blockers, gene-based therapy, and bisphosphonate

The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/10.2174/1573397117666211116111738